Twenty-five-year-old Woman with Bilateral Borderline Ovarian Tumour Desiring to Preserve Fertility – Case Report and Literature Review on the Current State of Fertility Preservation in Women with Borderline Ovarian Tumours

Abstract

Borderline ovarian tumours are semimalignant tumours occurring unilaterally or bilaterally with a peak incidence among women of reproductive age. Since the affected women often wish to preserve fertility, particular precautions must be taken when counselling the patient and obtaining consent prior to planning an individual treatment. Options for preserving fertility include an organ-sparing surgical procedure and cryopreservation of oocytes and/or ovarian tissue. In this article, we report on a 25-year-old patient with a bilateral seromucinous borderline tumour who desired all fertility-preserving options. In order to perform the procedure without delay, we opted to perform luteal phase stimulation prior to oocyte retrieval. We conclude by discussing the current literature on the state of fertility preservation in the treatment of borderline ovarian tumours.

Zusammenfassung

Borderline-Tumoren des Ovars sind semimaligne ein- oder beidseitig auftretende Tumoren, die ihren Altersgipfel bei Frauen im reproduktiven Alter haben. Da die betroffenen Frauen häufig einen Kinderwunsch hegen, ergeben sich besondere Notwendigkeiten der Aufklärung vor der Planung einer individuellen Therapie. Möglichkeiten des Erhalts der Fertilität sind ein organschonendes operatives Vorgehen sowie die Kryokonservierung von Eizellen und/oder Eierstockgewebe. Wir berichten über eine 25-jährige Patientin mit beidseitigem seromuzinösem Borderline-Tumor, die alle Optionen des Fertilitätserhalts wünschte. Um die Operation zeitnah durchführen zu können, entschieden wir uns für eine Lutealphasenstimulation vor der Follikelpunktion. Abschließend diskutieren wir die aktuelle Literatur zum Stand der Fertilitätsprotektion beim ovariellen Borderline-Tumor.

Key words

borderline tumour - fertility preservation - future wish for child - luteal phase stimulation - ovarian cryopreservation

Schlüsselwörter

Borderline-Tumor - Fertilitätserhalt - späterer Kinderwunsch - Lutealphasenstimulation - Kryokonservierung von Ovargewebe und Eizellen

• References

• 1 Harlow BL, Weiss NS, Lofton S. Epidemiology of borderline ovarian tumours. J Natl Cancer Inst 1987; 78: 71-74
• 2 Scully RE. World Health Organization. International Classification of Tumours. Histological Typing of ovarian Tumors. 2nd. ed. Berlin, Heidelberg, New York, Tokio: Springer; 1999
• 3 Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol 2001; 11: 568-574
• 4 Nikrui N. Survey of clinical behavior of patients with borderline tumors of the ovary. Gynecol Oncol 1981; 12: 107-119
• 5 Patrono MG, Minig L, Diaz-Padilla I et al. Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment. Ecancermedicalscience 2013; 7: 379
• 6 Uzan C, Kane A, Rey A et al. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol 2010; 21: 55-60
• 7 Daraï E, Fauvet R, Uzan C et al. Fertility and borderline ovarian tumour: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update 2013; 19: 151-166
• 8 Parazzini F, Negri E, La V et al. Treatment for fertility and risk of ovarian tumours of borderline malignancy. Gynecol Oncol 1998; 68: 226-228
• 9 von Wolff M, Montag M, Dittrich R et al. Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkinʼs lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 2011; 284: 427-435
• 10 Findeklee S, Lotz L, Heusinger K et al. Fertility protection in female oncology patients: how should patients be counseled?. Geburtsh Frauenheilk 2015; 75: 1243-1249
• 11 Trillsch F, Mahner S, Ruetzel J et al. Clinical management of borderline ovarian tumors. Expert Rev Anticancer Ther 2010; 10: 1115-1124
• 12 Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer 2015; 51: 620-631
• 13 du Bois A, Petru E, Meier W et al. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Juni 2013. Online: http://www.awmf.org last access: 02.01.2016
• 14 Lee MC, Gray J, Han HS et al. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control 2010; 17: 162-172
• 15 Li A, Pasternak M, Duke C et al. The effect of practitioner education on fertility preservation awareness, perception and clinical practice. Obstet Gynecol 2015; 125: 8-9
• 16 Zanetta G, Rota S, Chiari S et al. Behaviour of borderline tumours with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19: 2656-2664
• 17 Trillsch F, Mahner S, Vettorazzi E. Surgical staging and prognosis in serous borderline ovarian tumors (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer 2015; 112: 660-666
• 18 Shim SH, Kim SN, Jung PS et al. Impact of surgical staging on prognosis in patients with borderline ovarian tumours: a meta-analysis. Eur J Cancer 2016; 54: 84-95
• 19 du Bois A, Ewald-Riegler N, de Gregorio N et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer 2013; 49: 1905-1914
• 20 Denschlag D, von Wolff M, Amant F et al. Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery. Gynecol Obstet Invest 2010; 70: 160-165
• 21 Beiner ME, Gotlieb WH, Davidson B et al. Infertility treatment after conservative management of borderline ovarian tumours. Cancer 2001; 92: 320-325
• 22 Fortin A, Morice P, Thoury A et al. Impact of infertility drugs after treatment of borderline ovarian tumours: results of a retrospective multicenter study. Fertil Steril 2007; 87: 591-596
• 23 Basille C, Olivennes F, Le C et al. Impact of gonadotropins and steroid hormones on tumour cells derived from borderline ovarian tumours. Hum Reprod 2006; 21: 3241-3245
• 24 von Wolff M, Thaler CJ, Frambach T et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 2009; 92: 1360-1365
• 25 Simi G, Obino ME, Casarosa E et al. Different stimulation protocols for oocyte cryopreservation in oncological patients: a retrospective analysis of single university centre. Gynecol Endocrinol 2015; 31: 966-970
• 26 Nekkebroeck J, Stoop D, Devroey P. A preliminary profile of women opting for oocyte cryopreservation for non-medical reasons. Hum Reprod 2010; 25: i15-i16
• 27 Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet 2013; 30: 11-24
• 28 Fain-Kahn V, Poirot C, Uzan C et al. Feasibility of ovarian cryopreservation in borderline ovarian tumours. Hum Reprod 2009; 24: 850-855
• 29 Donnez J, Dolmans MM, Pellicer J et al. Fertility preservation for age-related fertility decline. Lancet 2015; 385: 506-507
• 30 Lotz L, Montag M, van der Ven H et al. Xenotransplantation of cryopreserved ovarian tissue from patients with ovarian tumors into SCID mice—no evidence of malignant cell contamination. Fertil Steril 2011; 95: 2612-2614
• 31 Cho HY, Kyung MS. CA 19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched-case control study. Med Sci Monit 2014; 20: 1334-1339
• 32 Barnhill DR, OʼConnor DM. Management of ovarian neoplasms of low malignant potential. Oncology (Williston Park) 1991; 5: 21-26 discussion 26, 28, 31–32